BioWorld MedTech

Feb. 6, 2017

Elekta secures FDA clearance for Venezia cervical cancer treatment device

Elekta AB has received FDA clearance for its Venezia applicator for gynecological brachytherapy. The device is positioned to treat advanced-stage cervical cancer and has had a CE mark since last year. Read More

Wearable micropump from Cambridge cluster disrupts device design

Questions about device class persist regarding accessory guidance final

Seroba raises $108M in first close of third fund

Appointments and advancements

Financings

Product briefs

MDD's Stock Report

Other news to note

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

Sangamo presents primate data for prion suppressor ST-506

BioWorld Science

Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...

TREM2 agonists detailed in Pfizer patent

BioWorld Science

Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.

Roche reports new TREM2 agonists

BioWorld Science

F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...